ABECMA (idecabtagene vicleucel) is a B-cell maturation antigen (BCMA)-directed genetically modified autologous T cell immunotherapy indicated for the treatment of adult patients with relapsed or refractory multiple myeloma after two or more prior lines of therapy, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody.

This website is best viewed using the horizontal display on your tablet device.

This website is best viewed using the vertical display on your mobile device.

Why Wait to Give Your Patients a Possibility of Remission?1

Eligible adult patients include those who are:

Clock Icon

Increased slot availability means you can start ABECMA FASTER THAN EVER for your eligible patients.

PI=proteasome inhibitor.

Learn more about the
efficacy and safety of ABECMA

Start the ABECMA
process faster
than ever
—find a certified
treatment center near